4-Antibody AG, a < ?xml:namespace prefix = st1 />Basel, Switzerland-based antibody developer and optimizer, has raised around $13.66 million in additional Series A funding, bringing the round total to $18.5 million. Advent Venture Partners led the new tranche, and was joined by existing backers Life Sciences Partners, BioMedinvest AG, Grazia Equity and Mulligan Biocapital. www.4-antibody.com